TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02727634

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison cardiac power and cardiac power output at different time points in the perioperative period
Description: The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
Study: NCT04006834

Intervention type: OTHER
Intervention: No intervention involved
Description: No intervention involved

Intervention type: OTHER
Intervention: No intervention involved
Description: No intervention involved
Study: NCT04565977

Intervention type: OTHER
Intervention: Observational
Description: Retrospective chart review
Study: NCT02669576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind body medicine day care clinic
Description: Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
Study: NCT03059498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
Study: NCT02669576

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients continue usual care by their practitioner
Study: NCT03507972

Intervention type: RADIATION
Group type: OTHER
Intervention: ankle ultrasound
Description: Ankle ultrasound performed during emergencies visit.
Study: NCT04059094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Inhalation solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation solution
Study: NCT03507972

Intervention type: RADIATION
Group type: OTHER
Intervention: Member MRI
Description: Member MRI (without injection of contrast product) performed within 7 days following the trauma
Study: NCT02617693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.

Intervention type: OTHER
Group type: OTHER
Intervention: standard antenatal care
Description: Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
Study: NCT03876197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem/stromal cells
Description: Autologous adipose-derived mesenchymal stem/stromal cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
Study: NCT02628626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical in appearance to the active drug.
Study: NCT03457129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel Oral Tablet
Description: Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Oral Tablet
Description: Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
Study: NCT01335581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-Switched Nd:YAG Laser (RevLite)
Description: Laser treatment added to a microdermabrasion and topical lightening agent regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retin-A and microdermabrasion
Description: Microdermabrasion and topical lightening agent regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retin-A and microdermabrasion
Description: Microdermabrasion and topical lightening agent regimen
Study: NCT03336047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personal activity intelligence
Description: Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10,000 steps daily
Description: Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
Study: NCT04013724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group tobacco cessation interventions
Description: Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented.
Study: NCT04065906

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate or Tomoxetine
Description: Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
Study: NCT03701906

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus PS11603 & Bifidobacterium PS10402
Description: Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L.salivarius PS11603 and 1\*10E8 CFU of B.longum PS10402.
Study: NCT00396591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg administered intravenously (IV) once every 2 weeks
Study: NCT03701906

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
Study: NCT01534091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer with supervision

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer without supervision
Study: NCT03064360

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.

Intervention type: DEVICE
Intervention: Patient Activity
Description: Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
Study: NCT03932214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACCUVEIN
Description: The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
Study: NCT02170337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 282
Description: AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
Study: NCT03064360

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Symptom and quality of life questionnaire at baseline, and every week following to study completion
Study: NCT00525707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tezosentan
Description: tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tezosentan
Description: tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
Study: NCT05070533

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual treatment
Description: Participants will receive 7 home visits to implement the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Groupal treatment
Description: Subjects will participate in groups of about 8 - 12 to implement the program.
Study: NCT00512993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
Study: NCT01144923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin and/or Nortriptyline, Physical therapy
Description: Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injections (ESI)
Description: Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
Study: NCT02170337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active drug
Study: NCT00623337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visits
Description: Home visits by community based surveillance volunteers (2 during pregnancy \& 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify \& refer sick babies
Study: NCT03576092

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
Study: NCT01144923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination treatment
Description: Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
Study: NCT02667574

Intervention type: DRUG
Group type: OTHER
Intervention: ERIVEDGE
Study: NCT04472624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Acute fasting for 72 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Intake of a ketogenic diet for 14 days
Study: NCT01437215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventana Fenestrated Stent Graft System
Description: Endovascular repair of juxtarenal or pararenal aortic aneurysm
Study: NCT04356131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercises and massage
Description: Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
Study: NCT03032094

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: palatal connective tissue graft to attain root coverage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: palatal connective tissue graft to attain root coverage
Study: NCT00508807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 5 mg by mouth (PO) daily for 21 days
Study: NCT04855825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Exoskeleton Rehabilitation
Description: Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Therapy
Description: Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
Study: NCT04637789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the whole body vibration
Description: most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
Study: NCT01722071

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
Study: NCT01266512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL
Description: Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: 2 Gy per fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CISPLATIN
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study: NCT03251066

Intervention type: OTHER
Group type: OTHER
Intervention: Proponent Nasal Spray
Description: The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
Study: NCT02632539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual air-impingement operation
Description: A method which we invented to clear subglottic secretion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subglottic secretion drainage
Description: The conventional method which we use subglottic secretion drainage to clear subglottic secretion
Study: NCT04348929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires
Description: Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)

Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered questionnaires
Description: Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)

Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered questionnaires
Description: Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
Study: NCT04080817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neolexon
Description: Application (Neolexon) on Tablet. Same frequency \& intensity as in the other interventions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech therapy
Description: standard logopedic speech therapy. Same frequency \& intensity as in the other interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self training
Description: Same frequency \& intensity as in the other interventions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self training
Description: Same frequency \& intensity as in the other interventions
Study: NCT01040897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication and Obesity Prevention
Description: Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Arm
Description: Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
Study: NCT01705652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexrutine
Description: Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexrutine
Description: Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
Study: NCT03524612

Intervention type: DRUG
Group type: OTHER
Intervention: eltrombopag
Description: 12.5, 25, 50 and 75 mg tablets for oral use once daily
Study: NCT04690751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate 200Mg Tab Fasted
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate Oral Suspension Fed
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobomate Oral Suspension Fasted
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
Study: NCT03326258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glembatumumab Vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00656474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Administration of Placebo gel on Day 1, 3 and 5 post ablation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 gel (1.0 %)
Description: Administration on Day 1, 3 and 5 post laser ablation.